EU Approves Imbruvica In MCL, CLL Patients

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The European Commission granted marketing approval for Imbruvica (ibrutinib) throughout the European Union, for relapsed or refractory mantle cell lymphoma, or chronic lymphocytic leukemia patients who have received at least one prior therapy, or in first line CLL patients in the presence of 17p deletion or TP53 mutation in patients unsuitable for chemotherapy.

Imbruvica, a first-in-class, oral, once-daily, non-chemotherapy treatment, is being jointly developed and commercialized in the U.S. by Pharmacyclics Inc. and Janssen Biotech Inc., which will market Imbruvica in Europe.

The approval was based on data from a phase II study in MCL, the phase III RESONATE study in CLL and small lymphocytic lymphoma and the phase Ib/II study in CLL/SLL. A worldwide regulatory filing program for ibrutinib currently is underway, according to the drug’s sponsor.

Imbruvica is approved in the U.S. for three indications: for the treatment of patients with MCL and CLL who have received at least one prior therapy, and for the treatment of CLL patients with deletion of the short arm of chromosome 17, including treatment-naive and previously treated del 17p CLL patients.

Pharmacyclics also entered into a master clinical drug supply agreement with Roche to evaluate the safety, tolerability and preliminary efficacy of Imbruvica in combination with Gazyva (obinutuzumab), a CD20-directed antibody that attacks targeted cells both directly and together with the body’s immune system, in patients with non-Hodgkin lymphoma and chronic lymphocytic leukemia/small lymphocytic lymphoma.

Initially, a phase III study will be conducted by Pharmacyclics in CLL/SLL. Plans to evaluate the combination for NHL currently are in development. Gazyva is a registered trademark of Genentech Inc.

The study of the investigational combination of Imbruvica and Gazyva through several investigator-sponsored trials also is being considered. Additional details of the agreement were not disclosed.

Janssen Research & Development also submitted a supplemental New Drug Application for Imbruvica to FDA for the treatment of patients with Waldenstrom’s macroglobulinemia. If approved, this will become the fourth indication for Imbruvica, which received an FDA Breakthrough Therapy Designation for WM in February 2013.

YOU MAY BE INTERESTED IN

For nearly 25 years, business executive Lou Weisbach and urologist Richard J. Boxer have argued that finding the money to finance the cures for devastating diseases is not as difficult as it appears. To start finding the cures, the U.S. Department of the Treasury needs to issue some bonds—$750 billion worth. Next, you hire CEOs—one...

There is general agreement that the United States spends too much on health care, especially on pharmaceuticals.  But what we spend on drugs is not simply a function of price. If eggs double in price, people can simply cut the number of eggs they eat in half.  Simply stated, cost is the product of (price per unit times the number of units purchased). 
What did President Richard M. Nixon and Senator Edward M. Kennedy have in common? They each played a pivotal role in the passage of the National Cancer Act signed by Nixon on Dec. 23, 1971. The NCA established the National Cancer Program authorizing the initial investment in the NCI-designated Cancer Centers Program. 
When I first proposed targeting PCNA (proliferating cell nuclear antigen) as a therapeutic approach, the response I got was: “No one will ever make a drug against PCNA. It’s undruggable.” The protein lacks enzymatic activity, has a disordered region, and binds to over 200 other proteins within the cell. From a traditional drug development perspective, these characteristics made PCNA an impossible target.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login